Skip directly to search Skip directly to A to Z list Skip directly to page options Skip directly to site content

Volume 23, Number 1—January 2017

CME ACTIVITY - Research

Analysis of Anthrax Immune Globulin Intravenous with Antimicrobial Treatment in Injection Drug Users, Scotland, 2009–2010

Xizhong Cui1, Leisha D. Nolen1, Junfeng Sun, Malcolm Booth, Lindsay Donaldson, Conrad P. Quinn, Anne E. Boyer, Katherine A. Hendricks, Sean Shadomy, Pieter Bothma, Owen Judd, Paul McConnell, William A. Bower, and Peter Q. EichackerComments to Author 
Author affiliations: National Institutes of Health, Bethesda, Maryland, USA (X. Cui, J. Sun, P.Q. Eichacker); Centers for Disease Control and Prevention, Atlanta, Georgia, USA (L.D. Nolen, C.P. Quinn, A.E. Boyer, K. Hendricks, S. Shadomy, W.A. Bower); Glasgow Royal Infirmary, Glasgow, UK (M. Booth, L. Donaldson); James Paget University Hospital, Norfolk, UK (P. Bothma); Royal Derby Hospital, Derby, UK (O. Judd); Crosshouse Hospital, Kilmarnock, UK (P. McConnell)

Main Article

Table 5

Microbiology data and the time to confirmatory anthrax diagnosis for recipients and nonrecipients of AIG-IV, Scotland, UK, 2009–2010*

Laboratory test AIG-IV nonrecipient AIG-IV recipient p value
Blood culture 32 (8/25) 71.4 (10/14) 0.02
Wound culture 46.2 (6/13) 33.3 (3/9) 0.67
Tissue culture 54.6 (6/11) 70 (7/10) 0.66
Blood PCR 29.4 (5/17) 80 (8/10) 0.02
Blood protective antigen antibody 81.3 (13/16) 66.7 (4/6) 0.59
Blood lethal factor antibody 62.5 (10/16) 57.1 (4/7) 1.00
Days to diagnosis, median (IQR) 3.5 (2.0–30.5), n = 28 2.0 (1.0–3.0), n = 13 0.006

*Values are % patients (no. patients with the finding/no. patients for whom data were available) except as indicated. n values indicate no. patients for whom data were available. Bold indicates significant differences between AIG-IV recipients and nonrecipients. AIG-IV, anthrax immune globulin intravenous; IQR, interquartile range.

Main Article

1These authors contributed equally to this article.

TOP